IMP dehydrogenase

Inhibition by the anti-leukemic drug, tiazofurin

Yasukazu Yamada, Yutaka Natsumeda, Yasufumi Yamaji, Hiremagalur N. Jayaram, Guido J. Tricot, Ronald Hoffman, George Weber

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Tiazofurin through its active metabolite thiazole-4-carboxamide adenine dinucleotide (TAD) inhibits IMP dehydrogenase, the rate-limiting enzyme of GTP biosynthesis. IMP dehydrogenase activity in human leukemic cell extracts (33.4 ± 0.1 nmol/h/mg protein) was increased 11-fold compared to normal leukocytes (3.1 ± 0.5). Km values for IMP and NAD+ of leukemic IMP dehydrogenase were 22.7 and 44.0 μM, respectively. XMP inhibited competitively with IMP and noncompetitively with NAD+. NADH exerted mixed type inhibition with respect to both IMP and NAD+. The inhibitory pattern of TAD was quite similar to that of NADH; however, the affinity of TAD to leukemic IMP dehydrogenase (Ki = 0.1 μM) was three orders of magnitude higher than the natural product NADH (Ki = 150 μM). These results contribute to an understanding of the mechanism of action of tiazofurin in the treatment of leukemia.

Original languageEnglish
Pages (from-to)179-184
Number of pages6
JournalLeukemia Research
Volume13
Issue number2
DOIs
StatePublished - 1989

Fingerprint

tiazofurin
IMP Dehydrogenase
NAD
Inosine Monophosphate
Pharmaceutical Preparations
Guanosine Triphosphate
Cell Extracts
Biological Products
Human Activities
Leukemia
Leukocytes

Keywords

  • IMP dehydrogenase
  • kinetics, tiazofurin, thiazole-4-carboxamide adenine dinucleotide, leukemia, chemotherapy, blast crisis of chronic granulocytic leukemia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Yamada, Y., Natsumeda, Y., Yamaji, Y., Jayaram, H. N., Tricot, G. J., Hoffman, R., & Weber, G. (1989). IMP dehydrogenase: Inhibition by the anti-leukemic drug, tiazofurin. Leukemia Research, 13(2), 179-184. https://doi.org/10.1016/0145-2126(89)90143-4

IMP dehydrogenase : Inhibition by the anti-leukemic drug, tiazofurin. / Yamada, Yasukazu; Natsumeda, Yutaka; Yamaji, Yasufumi; Jayaram, Hiremagalur N.; Tricot, Guido J.; Hoffman, Ronald; Weber, George.

In: Leukemia Research, Vol. 13, No. 2, 1989, p. 179-184.

Research output: Contribution to journalArticle

Yamada, Y, Natsumeda, Y, Yamaji, Y, Jayaram, HN, Tricot, GJ, Hoffman, R & Weber, G 1989, 'IMP dehydrogenase: Inhibition by the anti-leukemic drug, tiazofurin', Leukemia Research, vol. 13, no. 2, pp. 179-184. https://doi.org/10.1016/0145-2126(89)90143-4
Yamada Y, Natsumeda Y, Yamaji Y, Jayaram HN, Tricot GJ, Hoffman R et al. IMP dehydrogenase: Inhibition by the anti-leukemic drug, tiazofurin. Leukemia Research. 1989;13(2):179-184. https://doi.org/10.1016/0145-2126(89)90143-4
Yamada, Yasukazu ; Natsumeda, Yutaka ; Yamaji, Yasufumi ; Jayaram, Hiremagalur N. ; Tricot, Guido J. ; Hoffman, Ronald ; Weber, George. / IMP dehydrogenase : Inhibition by the anti-leukemic drug, tiazofurin. In: Leukemia Research. 1989 ; Vol. 13, No. 2. pp. 179-184.
@article{01376e845ee547e29504e062ec00d9c3,
title = "IMP dehydrogenase: Inhibition by the anti-leukemic drug, tiazofurin",
abstract = "Tiazofurin through its active metabolite thiazole-4-carboxamide adenine dinucleotide (TAD) inhibits IMP dehydrogenase, the rate-limiting enzyme of GTP biosynthesis. IMP dehydrogenase activity in human leukemic cell extracts (33.4 ± 0.1 nmol/h/mg protein) was increased 11-fold compared to normal leukocytes (3.1 ± 0.5). Km values for IMP and NAD+ of leukemic IMP dehydrogenase were 22.7 and 44.0 μM, respectively. XMP inhibited competitively with IMP and noncompetitively with NAD+. NADH exerted mixed type inhibition with respect to both IMP and NAD+. The inhibitory pattern of TAD was quite similar to that of NADH; however, the affinity of TAD to leukemic IMP dehydrogenase (Ki = 0.1 μM) was three orders of magnitude higher than the natural product NADH (Ki = 150 μM). These results contribute to an understanding of the mechanism of action of tiazofurin in the treatment of leukemia.",
keywords = "IMP dehydrogenase, kinetics, tiazofurin, thiazole-4-carboxamide adenine dinucleotide, leukemia, chemotherapy, blast crisis of chronic granulocytic leukemia",
author = "Yasukazu Yamada and Yutaka Natsumeda and Yasufumi Yamaji and Jayaram, {Hiremagalur N.} and Tricot, {Guido J.} and Ronald Hoffman and George Weber",
year = "1989",
doi = "10.1016/0145-2126(89)90143-4",
language = "English",
volume = "13",
pages = "179--184",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - IMP dehydrogenase

T2 - Inhibition by the anti-leukemic drug, tiazofurin

AU - Yamada, Yasukazu

AU - Natsumeda, Yutaka

AU - Yamaji, Yasufumi

AU - Jayaram, Hiremagalur N.

AU - Tricot, Guido J.

AU - Hoffman, Ronald

AU - Weber, George

PY - 1989

Y1 - 1989

N2 - Tiazofurin through its active metabolite thiazole-4-carboxamide adenine dinucleotide (TAD) inhibits IMP dehydrogenase, the rate-limiting enzyme of GTP biosynthesis. IMP dehydrogenase activity in human leukemic cell extracts (33.4 ± 0.1 nmol/h/mg protein) was increased 11-fold compared to normal leukocytes (3.1 ± 0.5). Km values for IMP and NAD+ of leukemic IMP dehydrogenase were 22.7 and 44.0 μM, respectively. XMP inhibited competitively with IMP and noncompetitively with NAD+. NADH exerted mixed type inhibition with respect to both IMP and NAD+. The inhibitory pattern of TAD was quite similar to that of NADH; however, the affinity of TAD to leukemic IMP dehydrogenase (Ki = 0.1 μM) was three orders of magnitude higher than the natural product NADH (Ki = 150 μM). These results contribute to an understanding of the mechanism of action of tiazofurin in the treatment of leukemia.

AB - Tiazofurin through its active metabolite thiazole-4-carboxamide adenine dinucleotide (TAD) inhibits IMP dehydrogenase, the rate-limiting enzyme of GTP biosynthesis. IMP dehydrogenase activity in human leukemic cell extracts (33.4 ± 0.1 nmol/h/mg protein) was increased 11-fold compared to normal leukocytes (3.1 ± 0.5). Km values for IMP and NAD+ of leukemic IMP dehydrogenase were 22.7 and 44.0 μM, respectively. XMP inhibited competitively with IMP and noncompetitively with NAD+. NADH exerted mixed type inhibition with respect to both IMP and NAD+. The inhibitory pattern of TAD was quite similar to that of NADH; however, the affinity of TAD to leukemic IMP dehydrogenase (Ki = 0.1 μM) was three orders of magnitude higher than the natural product NADH (Ki = 150 μM). These results contribute to an understanding of the mechanism of action of tiazofurin in the treatment of leukemia.

KW - IMP dehydrogenase

KW - kinetics, tiazofurin, thiazole-4-carboxamide adenine dinucleotide, leukemia, chemotherapy, blast crisis of chronic granulocytic leukemia

UR - http://www.scopus.com/inward/record.url?scp=0024560145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024560145&partnerID=8YFLogxK

U2 - 10.1016/0145-2126(89)90143-4

DO - 10.1016/0145-2126(89)90143-4

M3 - Article

VL - 13

SP - 179

EP - 184

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 2

ER -